Trials / Completed
CompletedNCT01778023
Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature
A 12-month, Open-labelled, Randomised, Parallel-group, Multi-centre, Interventional Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone (hGH) (Norditropin® Nordilet®) Therapy on Height Velocity (Ht-V) in Patients With Idiopathic Short Stature in Korea
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 4 Years – 11 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in Asia. The aim of this trial is to evaluate the efficacy and safety of recombinant human growth hormone (hGH) in subjects with idiopathic short stature in Korea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | somatropin | A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week. |
Timeline
- Start date
- 2013-01-17
- Primary completion
- 2014-12-17
- Completion
- 2014-12-17
- First posted
- 2013-01-29
- Last updated
- 2017-06-02
- Results posted
- 2016-10-05
Locations
8 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01778023. Inclusion in this directory is not an endorsement.